IBP
Installed Building Products, Inc.
IBP has lower modeled downside risk, despite its lower overall score.
LCID
Lucid Group, Inc.
LCID has the edge over IBP overall, supported by stronger modeled upside and stronger valuation.
IBP Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Healthy |
IBP's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
IBP PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $151 | -33% |
| Fair | 24x | $214 | -4.3% |
| Forward | 24x | $224 | — |
| Current | 26x | $224 | — |
| Expensive | 33x | $292 | +31% |
Historical ranges are pointers, not guarantees.
IBP's PE is in its fair range at 26x. On analysts' estimates for next year's earnings, today's price would be 24x.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
IBP Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Decline | |
| Stable | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect IBP's earnings and profitability to decline, with its revenue holding steady.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
IBP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.38 | +6.9% |
| Q3 2026 | $8.77 | -5.6% |
| Q2 2026 | $9.27 | +3.1% |
| Q1 2026 | $9.36 | +6.7% |
| Q4 2025 | $9.71 | +6.7% |
| Q3 2025 | $9.29 | +3.2% |
| Q2 2025 | $8.99 | +0.3% |
| Q1 2025 | $8.77 | -0.8% |
| Q4 2024 | $9.10 | +5.7% |
IBP has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
IBP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $808.4M | +3.9% |
| Q2 2026 | $777.8M | +2.3% |
| Q1 2026 | $660.5M | -3.5% |
| Q4 2025 | $747.5M | -0.4% |
| Q3 2025 | $778.2M | +2.3% |
| Q2 2025 | $760.3M | +3.1% |
| Q1 2025 | $684.8M | -1.2% |
| Q4 2024 | $750.2M | +4.1% |
IBP's revenue grew through 2023 and has held roughly level since: $808M last quarter, up 3.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | -2.4 points |
| Q2 2026 | 12% | -1.1 points |
| Q1 2026 | 8.7% | -1.5 points |
| Q4 2025 | 15% | +1.4 points |
| Q3 2025 | 14% | +0.4 points |
| Q2 2025 | 13% | +0.4 points |
| Q1 2025 | 10% | -2.5 points |
| Q4 2024 | 13% | -0.4 points |
IBP has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over IBP on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
IBP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $58.3M | -44% |
| Q2 2026 | $51.9M | -31% |
| Q1 2026 | $85.7M | +19% |
| Q4 2025 | $49.3M | -6.8% |
| Q3 2025 | $104.8M | +36% |
| Q2 2025 | $74.8M | +29% |
| Q1 2025 | $71.9M | +14% |
| Q4 2024 | $52.9M | -29% |
IBP has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
IBP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -206K shares |
| 1 year | -2.5% | -666K shares |
| 3 years | -6.4% | -1.8M shares |
| 5 years | -11% | -3.1M shares |
| Available history | -11% | -3.4M shares |
IBP has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $76.3M |
| Q1 2026 | $25.4M |
| Q4 2025 | $37.7M |
| Q3 2025 | $51.4M |
| Q2 2025 | $49.2M |
| Q1 2025 | $34.3M |
| Q4 2024 | $78.9M |
IBP spent $139M buying back its own shares over the past year, down 35% from the year before.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
IBP Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.5x | Healthy |
| Q2 2026 | 1.6x | Healthy |
| Q1 2026 | 1.4x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.3x | Healthy |
IBP's net debt is about 1.5 years of its operating earnings (EBITDA), up from 1.3 years a year ago.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
IBP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.4 | Neutral |
| Stochastic | 55.5 | Neutral |
IBP's weekly RSI is 50 (neutral) and its Stochastic is 55 (neutral).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
IBP PE vs Consumer Cyclical Sector
| Metric | IBP | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 18x | 42% above |
| PE % | 52 | 47 | 5 pts above |
IBP is trading at 26x earnings, a 42% premium to the Consumer Cyclical sector's median of 18x.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
IBP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $202.6 | 10% above |
| 20 week MA | $218.5 | 2.4% above |
| 50 week MA | $249.9 | 10% below |
| 100 week MA | $227.4 | 1.6% below |
| 200 week MA | $201.6 | 11% above |
IBP has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
IBP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $69.1 | $108.7 | +57% |
| 2021 | $108.7 | $139.0 | +28% |
| 2022 | $139.0 | $87.5 | -37% |
| 2023 | $87.5 | $182.8 | +109% |
| 2024 | $182.8 | $174.3 | -4.6% |
| 2025 | $174.3 | $267.2 | +53% |
| 2026 YTD | $267.2 | $223.8 | -16% |
IBP has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.